In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression. Results of a new study support the hypothesis that iron ...

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements. Regeneron has once again received a complete response ...

Xelafaslatide (formerly ONL1204) is a small-molecule Fas inhibitor designed to protect key retinal cells from cell death that occurs across multiple retinal diseases and conditions such as geographic ...

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes. As retinal care continues to advance, ophthalmologists are ...

Innovative retinal therapies are advancing through FDA trials, promising breakthroughs in treating various retinal diseases. The retina field continues to see significant developments in the FDA ...

This study indicated that by analyzing the data of one of the most extensive GA patient cohorts in the Nordic countries, it established a data set on the long-term treatment-naive GA growth dynamics.

A panelist discusses how integrating clinical trial data with real-world experience, patient-centered care, and shared decision-making enables retina specialists to individualize treatment plans, ...

Belite Bio recently announced the acceptance of its New Drug Application (NDA) with priority review for tinlarebant by the Center for Drug Evaluation of China’s National Medical Products ...